Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
STROthis companySutro Biopharma, Inc.	$9.71	-0.51×	-0.74×	0.96×	-0.38×	-557.0%	92.9%	-102.4%	-186.5%	144.3%	-98.5%	-182.0%	-0.12×	0.29×	-2.75×	2.01×	0.0%	3	-8.69	2	C
ARTVArtiva Biotherapeutics, Inc.	$4.22	-1.25×	0.95×	0×	-1.1×	-84.3%	0.0%	0.0%	0.0%	-76.3%	-74.9%	-75.7%	0.1×	0.19×	0×	8.61×	0.0%	1	4.66	2	C+
CNTBConnect Biopharma Holdings Limited	$0.74	-2.82×	3.74×	2,452.52×	-2.19×	-15.8%	100.0%	-90740.6%	-86687.5%	-132.2%	-135.7%	-32.9%	0.02×	0.69×	0×	3.74×	0.0%	2	-15.61	2	C+
DTILPrecision BioSciences, Inc.	$10.50	-1.17×	0.58×	1.56×	0.68×	-257.3%	100.0%	-152.2%	-133.4%	-49.6%	-35.5%	-123.6%	0.31×	1.93×	-36.67×	13.32×	0.0%	3	-4.84	1	C-
GUTSFractyl Health, Inc.	$0.92	-2.39×	35.68×	0×	-2.27×	52.9%	0.0%	0.0%	0.0%	-1490.3%	-89.5%	-26.9%	6.52×	0.14×	0×	4.78×	0.0%	2	-13.45	2	C+
KLRSKalaris Therapeutics Inc	$2.49	-2.96×	1.63×	0×	-0.77×	212.6%	0.0%	0.0%	0.0%	-55.1%	-41.1%	-33.5%	0.02×	2.3×	-31.98×	12.23×	0.0%	0	-2.38	3	B
Peer median	—	-2.39×	1.63×	0×	-1.1×	-15.8%	0.0%	0.0%	0.0%	-76.3%	-74.9%	-33.5%	0.1×	0.69×	0×	8.61×	0.0%	2	-4.84	2	—